The claims in Allergan’s lawsuit against Valeant and William Ackman are of the ho-hum type that targets often raise to fend off – or at least slow down – a bidder, write Peter J. Henning and Steven Davidoff Solomon.

from DealBook» Mergers & Acquisitions http://ift.tt/1tDJVR5
via IFTTT

Publicités